about
Modern prognostic factors and angiogenesis in chronic lymphocytic leukemia: more data needed.Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumabPractical approach to management of chronic lymphocytic leukemiaFive years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia.Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia.Venous thromboembolism in patients with chronic lymphocytic leukemia.Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.Prothrombotic changes due to an increase in thyroid hormone levels.Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?Why R-CHOP for first line treatment of chronic lymphocytic leukemia?Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samplesTEM ExosomeAnalyzer: a computer-assisted software tool for quantitative evaluation of extracellular vesicles in transmission electron microscopy imagesPrognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemiaRole of angiogenesis in chronic lymphocytic leukemiaThe prognostic role of CLLU1 in chronic lymphocytic leukaemiaEfficacy of pneumococcal vaccination in chronic lymphocytic leukemia: should we rely on surrogate markers?Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemiaExpression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the diseaseDiffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapyFludarabine-induced autoimmune hemolytic anemia in a CLL patient: rituximab as the treatment of choice?Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphomThe outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
P50
Q31117966-7A63BC77-53E8-40C4-B829-8CAF4C463226Q33402561-20C40FEC-69FC-4626-AE4C-34BDA22E7836Q33419843-F97E31DE-9848-4782-8217-185F911569E7Q33438825-7F63C4E9-AA8A-42AA-B42F-B50A0D5A22A3Q35076449-0632857F-9C49-48F1-B0B3-97E72055EEA6Q36845277-40263FD3-6CD7-4917-9D5D-F7B46A1BD4EBQ36845282-99FB6007-9669-47F0-A840-3C2922612BF9Q38801001-2C9D806D-40DC-4E71-9B08-11838C6EF790Q38801007-9339E216-3CDD-4AF4-B50D-6196FE080FB6Q39635163-559ECE2E-D011-4105-BA26-108BF964A438Q40207789-6082C0FF-A6CE-4E5C-8DAA-D0922B7B4130Q40431314-B1AFFAC1-8841-4861-8CE8-D2A8987AE1AFQ40532403-FFB38872-D68C-4644-B14D-BF5F4F8AC1ACQ40736899-DACBDE1E-1878-4CA6-A857-CBBF74A7054CQ41137752-05A01D0B-DF0F-4307-B957-0A3F267EA195Q41503706-A3BEB50F-4A9E-4DFC-B2A0-EEF2908B236FQ41507971-85AEBFBA-3CFF-4D77-A675-8BF3DE894F67Q45806334-397B9FFE-B024-4E38-B8A6-C78CE8D2AA48Q45993077-DF73C1E7-C60C-41E0-87FF-5EA5689BAD36Q46412361-BD5389DF-E61D-4166-B0B6-D76A0DA77717Q46910811-FB3EAECB-2DE9-4BBD-9FB4-2476C2F00045Q48751476-F24B4F91-F1A0-4971-958B-99AF9B5C6EB2Q53098391-E736CE4D-3D94-435F-AF81-FCD6C60D62D2Q53151256-CD208AC0-48A4-4714-9D14-31F0F5E7E0B8Q54616772-EB1D1CFC-E1DF-4D50-A183-825E4374A4CEQ56896304-43B4EA88-ABF8-430C-B62E-1A38203757D1Q61812491-E208CC93-A8D6-4313-B30E-58BEDD885579Q62112104-E9842503-A63D-4E2A-A46B-C95FCA6498B8Q79304016-AA5FEF4E-EF29-4EC3-9A03-EF75C4FBEF73Q79952951-1FBF4126-C348-4492-95EB-719BBAD7375FQ80719180-C4A2E598-CCAC-48D8-B94D-6A5C6E1B5A64Q80772950-55B8FA1D-0DFF-4781-B3E5-ED75A445FFE0Q81274870-DE521D2A-F3F8-4AF2-B3AD-0AA252C6CB2AQ83184674-3036E1F6-4B3D-490F-9DB1-5372A82C6707Q83824234-00DF9C51-2B6F-4F65-A4F1-71A67B6FB35FQ85830551-19D27E8A-9B90-4E45-B31C-31BF4B536EE3Q86419722-F600B059-9542-4D91-9BBE-9B09BCEF3568
P50
description
lékař, hematolog a onkolog
@cs
researcher, ORCID id # 0000-0002-4187-8595
@en
wetenschapper
@nl
name
Lukas Smolej
@ast
Lukas Smolej
@es
Lukas Smolej
@nl
Lukáš Smolej
@cs
Lukáš Smolej
@en
type
label
Lukas Smolej
@ast
Lukas Smolej
@es
Lukas Smolej
@nl
Lukáš Smolej
@cs
Lukáš Smolej
@en
prefLabel
Lukas Smolej
@ast
Lukas Smolej
@es
Lukas Smolej
@nl
Lukáš Smolej
@cs
Lukáš Smolej
@en
P106
P1153
13007511300
P214
153149841870902840056
P31
P496
0000-0002-4187-8595
P691
P7859
viaf-153149841870902840056